title: Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
abstract: Mutations in canine parvovirus (CPV) field isolates have created concerns regarding the ability of vaccines containing CPV-2 to protect against infection with the newly identified antigenic types CPV-2b and CPV-2c. To address this concern, the efficacy of CPV-2 strain NL-35-D currently in use as a commercial vaccine was demonstrated against an oral challenge with CPV-2b and CPV-2c, respectively. Clinically healthy specific pathogen free Beagle dogs were either vaccinated or treated with water for injection first at 8-9 weeks of age and again at 11-12 weeks of age. All dogs were challenged either with CPV-2b or CPV-2c three weeks after the second vaccination. During the two week period following challenge, clinical signs, white blood cell counts, serology by haemagglutination inhibition (HI) and serum neutralisation tests, and virus shedding by haemagglutination test were assessed. All control dogs developed clinical signs of parvovirosis (including pyrexia and leucopenia) and shed virus. Vaccinated dogs seroconverted (HI titres > or =80), remained healthy throughout the study and shed more than 100 times less virus than controls. In conclusion, vaccination with the low passage, high titre CPV-2 strain NL-35-D cross-protects dogs against virulent challenges with CPV-2b or CPV-2c by preventing disease and substantially reducing viral shedding.
authors.affiliation: Veterinary Medicine Research and Development, Pfizer Animal Health, Harlan Laboratories Bioservice GmbH2.
authors.forename: Elisabeth M
authors.initials: EM
authors.lastname: Siedek
authors.forename: Holger
authors.initials: H
authors.lastname: Schmidt
authors.forename: Gordon H
authors.initials: GH
authors.lastname: Sture
authors.forename: Rüdiger
authors.initials: R
authors.lastname: Raue
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D004283:Dog Diseases / Q000517:prevention & control* / Q000821:virology; D004285:Dogs; D005243:Feces / Q000821:virology; D006385:Hemagglutination Inhibition Tests / Q000662:veterinary; D006386:Hemagglutination Tests / Q000662:veterinary; D007958:Leukocyte Count / Q000662:veterinary; D009154:Mutation; D009500:Neutralization Tests / Q000662:veterinary; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D017993:Parvovirus, Canine / Q000145:classification / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000145:classification; D014765:Viral Vaccines / Q000145:classification; D014774:Virulence; D017201:Virus Shedding / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines